Lonza Group AG (SWX:LONN)
503.80
-4.40 (-0.87%)
Apr 23, 2026, 11:35 AM CET
Lonza Group AG Revenue
In the year 2025, Lonza Group AG had annual revenue of 6.53B CHF with 19.18% growth. Lonza Group AG had revenue of 2.96B in the half year ending December 31, 2025, a decrease of -18.80%.
Revenue
6.53B
Revenue Growth
-0.65%
P/S Ratio
5.43
Revenue / Employee
326.55K
Employees
20,000
Market Cap
35.49B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.53B | 1.05B | 19.18% |
| Dec 31, 2024 | 5.48B | -1.24B | -18.42% |
| Dec 31, 2023 | 6.72B | 494.00M | 7.94% |
| Dec 31, 2022 | 6.22B | 814.00M | 15.05% |
| Dec 31, 2021 | 5.41B | 901.00M | 19.99% |
| Dec 31, 2020 | 4.51B | 301.00M | 7.15% |
| Dec 31, 2019 | 4.21B | -1.34B | -24.09% |
| Dec 31, 2018 | 5.54B | 994.00M | 21.86% |
| Dec 31, 2017 | 4.55B | 416.00M | 10.07% |
| Dec 31, 2016 | 4.13B | 329.00M | 8.65% |
| Dec 31, 2015 | 3.80B | 163.00M | 4.48% |
| Dec 31, 2014 | 3.64B | 56.00M | 1.56% |
| Dec 31, 2013 | 3.58B | -341.00M | -8.69% |
| Dec 31, 2012 | 3.93B | 1.23B | 45.80% |
| Dec 31, 2011 | 2.69B | 12.00M | 0.45% |
| Dec 31, 2010 | 2.68B | -10.00M | -0.37% |
| Dec 31, 2009 | 2.69B | -247.00M | -8.41% |
| Dec 31, 2008 | 2.94B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Roche Holding AG | 63.36B |
| Novartis AG | 44.94B |
| Sandoz Group AG | 8.85B |
| Alcon | 8.25B |
| Galderma Group AG | 4.16B |
| Galenica AG | 4.15B |
| Sonova Holding AG | 3.85B |
| Straumann Holding AG | 2.61B |
Lonza Group AG News
- 1 day ago - Simulations Plus (SLP) Partners with FDA and Lonza for Drug Performance Research - GuruFocus
- 6 weeks ago - Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG - Business Wire
- 2 years ago - Lonza chairman to step down, drugmaker confirms targets, shares soar - Reuters
- 2 years ago - Lonza CEO departure prompts concern over earnings prospects - Reuters
- 3 years ago - 10 Solid Stocks WIth Terrible Tickers - Barrons
- 4 years ago - Lonza's first-half core EBITDA gains 16.5% - Reuters
- 4 years ago - Should You Have Lonza Stock on Your Watchlist? - The Motley Fool
- 5 years ago - Lonza appoints Novartis executive as new Chief Financial Officer - Reuters